Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


GSK Avandia settlement: round one in a long legal fight

12:38 pm by | 1 Comments

GlaxoSmithKline has settled its first case involving former diabetes blockbuster Avandia, but it will most certainly not be the last word on the matter.

The London-based pharmaceutical company, which has its U.S. headquarters in North Carolina’s Research Triangle Park, settled Deborah A. Burford v. SmithklineBeecham Corp. just before the trial was scheduled to start today. Deborah Burford sued GSK (NYSE:GSK) after the death of her husband James Burford, a North Carolina man who used Avandia for 15 months for his diabetes before dying of a heart attack in 2006. The suit claimed GSK refused to take Avandia off the market despite studies showing that the drug increased the risks of heart attacks and strokes.

GSK still faces thousands of additional lawsuits regarding Avandia, which was suspended from the European market in September and allowed to remain in the U.S. market only with strict warnings. Those restrictions followed growing scrutiny of the drug last summer as U.S. and European regulators continued to probe alleged ties of the drug to increased cardiovascular risks.

To get a better sense of how this legal settlement could play out for GSK, consider another former blockbuster drug whose downfall followed links to cardiovascular risks: Vioxx. Merck (NYSE:MRK) withdrew the drug in 2004 after clinical studies showed the drug increased risks of heart attack and stroke. A flood of lawsuits followed. Merck chose to litigate, rather than settle. It lost its first case, resulting in a $253 million award to the plaintiff. But Merck won many of the subsequent cases that went before juries, making settlement a more attractive option for many plaintiffs. In 2007, Merck agreed to pay $4.85 billion to settle more than 26,000 cases.

Advertisement

Terms of the settlement in the Burford case were not disclosed. The lawsuit had sought damages of $1.3 million to cover economic damages, including the loss of Burford’s income. Non-economic damages, such as pain and suffering, emotional distress and punitive damages to GSK, were to be determined at trial.

It’s not yet clear whether the Burford settlement could pave the way for future Avandia settlements. But GSK has armed itself for the legal battle; this month the company announced it was setting aside $3.4 billion to pay for legal costs related to Avandia. How the next few Avandia trials shake out could determine whether GSK will be reaching settlements with most of its plaintiffs or whether the company will choose to litigate the cases in hopes of winning some decisions. Either way, GSK will pay. Don’t be surprised if GSK makes additional announcements of legal charges reaching into the billions of dollars.

Enhanced by Zemanta

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Frank Vinluan

Frank Vinluan is the North Carolina Bureau Chief for MedCity News.
More posts by Author

1 comments
harold burns
harold burns

I wish to join the list of complaiments to claim for my wife who died from use of avandia on 16.12.2007.she started with the drug in feb 2007.